The fight against pancreatic cancer has taken a step forward in Germany, with 120 hospitals now legally entitled to negotiate funding for OncoSil Medical’s (ASX:OSL) innovative treatment device. This marks a 43% increase from the previous year and highlights growing recognition of the OncoSil™ device within the German healthcare system. German Hospitals Embrace OncoSil’s Innovation
Read More
Tackling a Major Health Challenge Gastrointestinal (GI) diseases, including colorectal cancer, are a significant global health issue. In 2020 alone, there were an estimated 1.9 million new cases of colorectal cancer and more than 930,000 related deaths worldwide. Early detection and precise intervention are crucial, but traditional diagnostic methods often lack the real-time precision required
Read More
Slightly below expectations December 2024 quarter CPI data released today were warmly received by stock market investors. The stats, which have ramifications for Australia’s monetary policy settings, bolstered hopes that the Reserve Bank of Australia (RBA) will reduce its benchmark interest rate ahead of the next Federal election, which must be held by May 2025.
Read More
Amid a challenging retail landscape that has seen the collapse of major players like Catch, Harris Technology (ASX: HT8) has been treading water with its retail tech business but unearthed a rapidly firing refurbished tech business that is poised to breakout in 2025. For the December 2024 quarter, Harris Technology reported sales revenue of $3.6
Read More
In a strategic move to bolster its governance and corporate strategy, OncoSil Medical Limited (ASX:OSL), a leader in pancreatic cancer treatment innovation, has today appointed Ms. Lel Smits as a Non-Executive Director. The addition of Ms. Smits, a renowned figure in corporate governance and investor relations, signals OncoSil’s commitment to enhancing its market position and
Read More
RYONCIL® (remestemcel-L) becomes the first mesenchymal stromal cell (MSC) product approved by the US Food and Drug Administration (FDA) for any indication. RYONCIL® is also the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening condition with high mortality rates.
Read More
Calls from some quarters for the RBA to slip an interest rate cut into borrowers’ Christmas stockings have gone unheeded, with the Bank’s benchmark interest rate remaining at 4.35% following its December 2024 Board meeting. This closely-watched rate has now been set at 4.35% since December last year. What kept the RBA from changing the
Read More
“This ARCEMY® X order from the TVA is very much aligned with the US Scale Up growth strategy we have in place,” said AML3D CEO Sean Ebert, as the company announced a landmark A$2.27 million contract to supply the Tennessee Valley Authority (TVA) with its large-scale ARCEMY® X system. The deal marks AML3D’s strategic expansion beyond
Read More
Australia’s economic growth, as measured by the ABS-compiled chain volume GDP statistics that adjust for price increases, rose by a paltry 0.3% in the September 2024 quarter, to be just 0.8% higher on an annual (through the year) basis. The markets were expected Australia’s quarterly economic growth increase to be around 0.5% in the latest
Read More
Invion (ASX:IVX) surged higher after announcing that it had completed the dosing of the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane. The trial marks a significant milestone for Invion and is designed to evaluate the safety and efficacy of its lead drug candidate
Read More
